The Food and Drug Administration is set to announce soon whether it will grant full approval to lecanemab for the treatment of Alzheimer’s.
Read Full Story
Latest posts by Market Watch (see all)
- : ‘Ability is ageless’: New York City helps retirees get back to work and fill open jobs - June 3, 2023
- : Beyond OpenAI: 7 promising startups that have saved lives, sped up drug development and improved manufacturing - June 3, 2023
- Biden signs debt ceiling bill that pulls U.S. back from brink of default - June 3, 2023